Compare SCLX & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | GRNQ |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.6M |
| IPO Year | 2020 | 2014 |
| Metric | SCLX | GRNQ |
|---|---|---|
| Price | $2.06 | $6.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.4K | ★ 66.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,253,000.00 | $3,673,997.00 |
| Revenue This Year | $118.16 | N/A |
| Revenue Next Year | $186.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.55 |
| 52 Week Low | $2.27 | $1.12 |
| 52 Week High | $27.00 | $318.00 |
| Indicator | SCLX | GRNQ |
|---|---|---|
| Relative Strength Index (RSI) | 14.46 | 37.87 |
| Support Level | N/A | $5.93 |
| Resistance Level | $7.77 | $12.05 |
| Average True Range (ATR) | 0.23 | 0.90 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 2.53 | 18.75 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.